The Mila artificial intelligence institute in Quebec is raising a US$100-million venture capital fund with plans to invest in more than 55 early-stage AI companies, in partnership with Inovia Capital ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Researchers at MIT's CSAIL published a design for Recursive Language Models (RLM), a technique for improving LLM performance on long-context tasks. RLMs use a programming environment to recursively ...

A recursive vibe journalism experiment in which Microsoft 365 Copilot's 'Prompt Coach' agent is used to wholly create an ...

New Rust release brings major improvements to musl’s DNS resolver and tweaks the standard library to aid global allocators.

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...